Cymabay Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cymabay Therapeutics Inc (CBAY) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cymabay Therapeutics Inc vs Its Competitors
- Profitability: Its -73,512.3% net margin compares with 28.4% for the peer group.
- Peer revenue share: Cymabay Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CBAY Sales vs. its Competitors, Q4 2023
With a net margin of -73,512.28 %, Cymabay Therapeutics Inc reported lower profitability than its competitors (28.39 %).
Cymabay Therapeutics Inc generated 0.00 % of the combined sales of its peer group.
Cymabay Therapeutics Inc vs. its Competitors, Q4 2023
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cymabay Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cymabay Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cymabay Therapeutics Inc's competitor groups requires a Commercial License.
Cymabay Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - | No |
| Competitors combined (20) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CBAY Stock Performance relative to its Competitors
CBAY Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 2 | Akero Therapeutics Inc | 282.9% | Outperformed |
| 3 | Zentalis Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Viking Therapeutics Inc | 282.9% | Outperformed |
| 5 | Vertex Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cymabay Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cymabay Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cymabay Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cymabay Therapeutics Inc | 3,449.52 | - |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| Horizon Therapeutics Public Limited Company | 27,190.33 | 3,643.45 |
| Madrigal Pharmaceuticals Inc | 15,069.27 | 1,283.94 |
| Biolinerx Ltd | 5,990.61 | 1.18 |
| SUBTOTAL | 283,150.69 | 34,420.40 |
Sign in to see all competitors of Cymabay Therapeutics Inc .
Sources: Cymabay Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cymabay Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cymabay Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Alfasigma S.p.A. | Named by the company | 85% |
| Mirum Pharmaceuticals Inc | Named by the company | 85% |
| Intercept Pharmaceuticals | Named by the company | 85% |
| Genfit S a | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cymabay Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cymabay Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Jaguar Health Inc | Human Health Segment 95.92 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cymabay Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cymabay Therapeutics Inc | 3,450 | - | -1,549,559 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| Horizon Therapeutics Public Limited Company | 27,190 | 2,802,652 | 336,925 |
| Madrigal Pharmaceuticals Inc | 15,069 | 1,403,213 | -355,295 |
| Biolinerx Ltd | 5,991 | 49,167 | -84,417 |
| PEERS TOTAL | 279,701 | 1,764,606 | 346,415 |
Sign in to see all peers for Cymabay Therapeutics Inc .
Cymabay Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cymabay Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 10.7x | 4.5x | +6.2x |
| Return on Equity | -50.72 % | industry aggregate | -64.12 % |
| Return on Invested Capital | -19.67 % | -2.95 % (avg) | -16.72 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cymabay Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -57.30 % | -77.85 % | -22.31 % | -25.58 % | - | -35.50 % | -40.89 % | -19.67 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cymabay Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 64.1 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (42.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-19.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cymabay Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cymabay Therapeutics Inc | 4.75 | 10.90 | - |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Horizon Therapeutics Public Limited Company | 2.57 | 4.04 | 0.50 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Biolinerx Ltd | 0.27 | 1.95 | - |
Sign in to see all peers for Cymabay Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cymabay Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cymabay Therapeutics Inc | Q4 2023 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | +7.7 % | +108.4 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Biolinerx Ltd | Q4 2025 | -95.9 % | - |
| PEERS TOTAL | +15.0 % | -14.0 % |
Sign in to see all peers for Cymabay Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cymabay Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cymabay Therapeutics Inc | Q4 2023 | - | +1,284.6 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Horizon Therapeutics Public Limited Company | Q2 2023 | -4.9 % | +81.9 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Biolinerx Ltd | Q4 2025 | -97.5 % | -52.8 % |
Sign in to see all peers for Cymabay Therapeutics Inc .
Cymabay Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Horizon Therapeutics Public Limited Company | 4.81% | 5.71% | 8.54% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Biolinerx Ltd | - | - | - |
Sign in to see all peers for Cymabay Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cymabay Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cymabay Therapeutics Inc | - | - |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| Horizon Therapeutics Public Limited Company | 62.49 | 7.46 |
| Madrigal Pharmaceuticals Inc | - | 11.74 |
| Biolinerx Ltd | - | 5,076.79 |
| PEERS AVERAGE | 42.57 | 8.23 |
Sign in to see all peers for Cymabay Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.